First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion

Thrombolex, Inc. — Mon, 22 Jan 2024 17:00:00 +0000

Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute intermediate-risk pulmonary embolism by Drs. Riyaz Bashir and Vladimir Lakhter, at Temple Universit...

The post First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion first appeared on HoustonNewMedia.org.

The post First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion appeared first on HoustonNewMedia.org.

Thrombolex, Inc. Has Received FDA Clearance for Use of BASHIR™ Endovascular Catheters for Treatment of Acute Pulmonary Embolism

Thrombolex, Inc. — Thu, 20 Apr 2023 22:00:00 +0000

Thrombolex, Inc. has received 510(k) clearance for use of the BASHIR™ and BASHIR™ S-B Endovascular Catheters for the treatment of acute pulmonary embolism (PE). [PR.com]

The post Thrombolex, Inc. Has Received FDA Clearance for Use of BASHIR™ Endovascular Catheters for Treatment of Acute Pulmonary Embolism first appeared on HoustonNewMedia.org.

The post Thrombolex, Inc. Has Received FDA Clearance for Use of BASHIR™ Endovascular Catheters for Treatment of Acute Pulmonary Embolism appeared first on HoustonNewMedia.org.

Thrombolex, Inc. - HoustonNewMedia.org

First Patient Enrolled In Thrombolex’s RESCUE II Study – On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion

Thrombolex, Inc. Has Received FDA Clearance for Use of BASHIR™ Endovascular Catheters for Treatment of Acute Pulmonary Embolism